Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2011-01-11
2011-01-11
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
C514S002600, C514S008100, C514S012200
Reexamination Certificate
active
07867481
ABSTRACT:
The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.
REFERENCES:
patent: 5075222 (1991-12-01), Hannum et al.
patent: 5998598 (1999-12-01), Csaky et al.
patent: 7087224 (2006-08-01), Kay et al.
patent: 0 393 438 (1990-04-01), None
patent: 0 422 339 (1998-01-01), None
patent: 0 855 404 (1998-07-01), None
patent: 0 148 605 (1998-12-01), None
patent: WO 96/09323 (1996-03-01), None
patent: WO 97/28828 (1997-08-01), None
patent: WO 98/01555 (1998-01-01), None
patent: WO 00/24893 (2000-05-01), None
patent: WO 00/26209 (2000-05-01), None
patent: WO 00/59530 (2000-10-01), None
patent: WO 02/096461 (2002-12-01), None
Galon et al. (2000), “TNFRSF1A Mutations and Autoinflammatory Syndroms,”Current Opinion in Immunology12: 479-486.
Glennie et al. (2000), “Clinical Trials of Antibody Therapy,”Immunology Today21(8): 403-410.
Lee et al. (1999), “Erythropoietin plus iron supplement prevents significant anemia during concurrent chemo-radiation therapy in patients with locally-advanced inoperable non-small cell lung cancer,”Proceedings of the American Association for Cancer Research Annual Meeting40: 642.
MacDougall et al. (1999), “Pharmacokinetics of Novel Erythropoietin Stimulating Protein Compared with Epoietin Alfa in Dialysis Patients,”J. Am. Society of Nephrology10: 2392-2395.
Means (1999), “Advances in the Anemia of Chronic Disease,”International J. of Hematol.70(1):7-12.
Means et al. (1999), “Commentary: An anemia of chronic disease, after all?,”J. Investigative Medicine47(5): 203.
Peeters et all. (1996), “Course and Characteristics of Anaemia in Patients with Rheumatoid Arthritis of Recent Onsent,”Ann. Rheum. Dis., 55: 162-68.
Pincus et al. (1990), “Multicenter Study of Recombinant Human Erythropoietin in Correction of Anemia in Rheumatoid Arthritis,”Am. J. Med.89:161.
Tanaka et al. (1999), “Autologous blood transfusion with recombinant erythropoietin treatment in anaemic patients with rheumatoid arthritis,”Clinical Rheumatology18(4): 293-298.
Voulgari, et al. (1999), “Role of Cytokines in the Pathogenesis of Anemia of Chronic Disease in Rheumatoid Arthritis,”Clin. Immunol.92:153-160.
Faquin et al. (1992), “Effect of Inflammatory Cytokines on Hypoxia-Induced Erythropoietin Production,”Blood79:1987-1994.
Means et al. (1992), “Progress in Understanding the Pathogenesis of the Anemia of Chronic Disease,”Blood80:1639-1647.
Nieken et al. (1995), “Recombinant Human Interleukin-6 Induces a Rapid and Reversible Anemia in Cancer Patients,”Blood86:900-905.
Smith et al. (1992), “Anaemia of chronic disease in rheumatoid arthritis: effect of the blunted response to erythropoietin and of interleukin 1 production by marrow macrophages,”Annals of the Rheumatic Diseases51: 753-757.
Sun et al. (1993), “The Influence of Recombinant Human Interleukin-6 on Blood and Immune Parameters in Middle-aged and Old Rhesus Monkeys,”Lymphokine Cytokine Research12:449-455.
Carter et al. (1990), “Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein,”Nature344:633-638.
Allen, D. A., et al., “Inhibition of CFU-E Colony Formation in Uremic Patients with Inflammatory Disease: Role of IFN-γ and TNF-α,” May 1999, J. Investig. Med., 47:204-211.
PubMed Abstract 12973441; Ghivizzani, S.C., et al., “Clinical gene therapy for arthritis,” Drugs Today, (Barc). Apr.-May 1999;35(4-5):389-96 (printed Mar. 31, 2005).
Coccia Marco A.
Kay Jonathan
McCabe Dorothy
Newmark Richard
Amgen Inc.
Hehman Mary K.
Mertz Prema
LandOfFree
Method of treating anemia by administering IL-1ra does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating anemia by administering IL-1ra, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating anemia by administering IL-1ra will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2687617